<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01638104</url>
  </required_header>
  <id_info>
    <org_study_id>ANX-042-C100</org_study_id>
    <nct_id>NCT01638104</nct_id>
  </id_info>
  <brief_title>ANX-042 Healthy Volunteer Dose Escalation Study</brief_title>
  <official_title>ANX-042 Healthy Volunteer Dose Escalation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Anexon, Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celerion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to investigate the safety and tolerability of ANX-042 when&#xD;
      administered by continuous intravenous (IV) infusion in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each participant received a total of two, approximately 12-hour continuous infusions of&#xD;
      ANX-042 and one 12-hour continuous infusion of placebo, with a 36-hour washout period between&#xD;
      treatments.&#xD;
&#xD;
      This study was conducted by Anexon, Inc. at Celerion, in Lincoln, Nebraska.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with one or more drug-related adverse events (AEs) or any serious AEs</measure>
    <time_frame>0 to 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area under the plasma concentration-time curve (AUC) of ANX-042</measure>
    <time_frame>0 to 24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Steady state plasma concentration of ANX-042</measure>
    <time_frame>12 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>ANX-042: 0.001 mcg/kg/min (with low sodium diet)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.001 dose unit equal to 1 millionth of a gram of an ANX-042 preparation / 1 kilogram of body mass administered / unit of time equal to 1 minute(mcg/kg/min), w/ diet restricted to 2.5 grams (gm) per day sodium (Na+) and 2.1 liters (L) fluid total daily intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ANX-042: 0.001 mcg/kg/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.001 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ANX-042: 0.003 mcg/kg/min (low sodium diet)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.003 mcg/kg/min ANX-042 with diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ANX-042: 0.003 mcg/kg/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.003 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ANX-042: 0.0065 mcg/kg/min (low sodium diet)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.0065 mcg/kg/min ANX-042 with diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ANX-042: 0.01 mcg/kg/min (low sodium diet)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.01 mcg/kg/min ANX-042 with diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ANX-042: 0.01 mcg/kg/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.01 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ANX-042: 0.03 mcg/kg/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.03 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ANX-042: 0.1 mcg/kg/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.1 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ANX-042: 0.3 mcg/kg/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.3 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (low sodium diet)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo and diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo and diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ANX-042</intervention_name>
    <description>Reconstituted in Sterile Water for Injection, United States Pharmacopeia (USP) and administered by 12 hour continuous intravenous infusion with 5% dextrose in water (D5W), United States Pharmacopeia (USP)</description>
    <arm_group_label>ANX-042: 0.001 mcg/kg/min</arm_group_label>
    <arm_group_label>ANX-042: 0.001 mcg/kg/min (with low sodium diet)</arm_group_label>
    <arm_group_label>ANX-042: 0.003 mcg/kg/min</arm_group_label>
    <arm_group_label>ANX-042: 0.003 mcg/kg/min (low sodium diet)</arm_group_label>
    <arm_group_label>ANX-042: 0.0065 mcg/kg/min (low sodium diet)</arm_group_label>
    <arm_group_label>ANX-042: 0.01 mcg/kg/min</arm_group_label>
    <arm_group_label>ANX-042: 0.01 mcg/kg/min (low sodium diet)</arm_group_label>
    <arm_group_label>ANX-042: 0.03 mcg/kg/min</arm_group_label>
    <arm_group_label>ANX-042: 0.1 mcg/kg/min</arm_group_label>
    <arm_group_label>ANX-042: 0.3 mcg/kg/min</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered once by 12 hour continuous intravenous infusion with D5W (USP)</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Placebo (low sodium diet)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women of non-reproductive potential (WNRP)&#xD;
&#xD;
               -  Men must be willing to use effective contraception and not donate sperm for up to&#xD;
                  90 days after the final dose of study drug&#xD;
&#xD;
               -  Women must be of non-reproductive potential defined as a history of surgical&#xD;
                  sterilization or postmenopausal status (that is, greater than ( &gt;) 50 years of&#xD;
                  age with &gt;12 months amenorrhea while not using hormonal contraceptives or &gt;50&#xD;
                  years of age with 6-12 months of amenorrhea and follicle stimulating hormone&#xD;
                  (FSH) level &gt;40 international unit/liter (IU/L)&#xD;
&#xD;
          -  Good health status, physically active without cardio-respiratory limitations and&#xD;
             minimal concomitant medications as determined by medical history and physical&#xD;
             examination&#xD;
&#xD;
          -  Able and willing to comply with study procedures, including controlled sodium (Na)&#xD;
             intake and restriction of caffeine and tobacco product&#xD;
&#xD;
          -  Have given written informed consent prior to the initiation of any study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of cardiovascular disease, unexplained syncope, postural tachycardia syndrome&#xD;
             or frequent postural hypotension&#xD;
&#xD;
          -  History or current evidence of respiratory, hepatic, renal, gastrointestinal,&#xD;
             endocrine, hematological or neurological disorders that would constitute a risk when&#xD;
             taking the study medication or interfere with the interpretation of data&#xD;
&#xD;
          -  Clinically significantly abnormal clinical laboratory results (including Hepatitis B,&#xD;
             Hepatitis C and Human Immunodeficiency Virus (HIV) serology) or physical examination&#xD;
             results (confirmed by repeat measurement, if appropriate) that, in the opinion of the&#xD;
             Investigator, would constitute a risk when taking the study medication or interfere&#xD;
             with the interpretation of data&#xD;
&#xD;
          -  Abnormal orthostatic Blood Pressure/Heart Rate (BP/HR) response at screening as&#xD;
             defined by:&#xD;
&#xD;
               -  Systolic Blood Pressure (BP) decrease &gt;20 millimeters of mercury (mmHg)&#xD;
&#xD;
               -  Diastolic BP decrease &gt;10 mmHg, or&#xD;
&#xD;
               -  HR increase &gt;25 beats per minute (bpm) and to a level above 100 bpm&#xD;
&#xD;
          -  One or two supine values must be obtained between 8 and 10 minutes of supine rest. One&#xD;
             or two upright values must be obtained between 3 and 5 minutes upright with the arm&#xD;
             passively supported to maintain the brachial artery at heart level&#xD;
&#xD;
          -  Abnormal 12-lead electrocardiogram (ECG) that interferes with proper measurement of&#xD;
             QT-interval or, in the opinion of the Investigator, increases the risk of&#xD;
             participating in the study&#xD;
&#xD;
          -  Elevated BP (&gt;140/90 mmHg) in any posture, confirmed by repeat measurement&#xD;
&#xD;
          -  Current use (within 7 days of first dosing) or expected need for concomitant&#xD;
             medications with hemodynamic effects including: non-steroidal anti-inflammatory drugs&#xD;
             (NSAIDS), decongestants, BP medications, diuretics, monoamine oxidase inhibitors,&#xD;
             norepinephrine uptake inhibitors (for example, attention-deficit disorder medications,&#xD;
             anti-depressants) and erectile dysfunction medications. Medications with low&#xD;
             likelihood of hemodynamic or renal effects are permitted (for example, acetaminophen,&#xD;
             vitamins, stable thyroid hormone, gastritis therapies, antihistamines, topical&#xD;
             medications, et cetera) after approval by the Investigator&#xD;
&#xD;
          -  Evidence of current or recent use of known drugs of abuse and/or positive findings on&#xD;
             urinary drug screening&#xD;
&#xD;
          -  History of an average weekly alcohol intake that exceeds 21 units per week (1 unit&#xD;
             equal to (=) 12 ounces (oz) or 360 milliliters (mL) of beer; 5 oz or 150 mL of wine;&#xD;
             1.5 oz or 45 mL of distilled spirits), or are unwilling to stop alcohol consumption&#xD;
             for the duration of the study&#xD;
&#xD;
          -  History of regular smoking of &gt;5 cigarettes, cigars and/or pipe bowls of tobacco per&#xD;
             day&#xD;
&#xD;
          -  Known allergies to nesiritide (Natrecor)&#xD;
&#xD;
          -  History of blood donation of &gt;500 mL within one month, or plasma donation within 14&#xD;
             days, of first dosing&#xD;
&#xD;
          -  Are currently enrolled in, or have completed or discontinued within the last 30 days&#xD;
             from, a clinical trial involving an investigational product or are concurrently&#xD;
             enrolled in any other type of medical research judged not to be scientifically or&#xD;
             medically compatible with this study&#xD;
&#xD;
          -  Are investigator site personnel directly affiliated with this study or their immediate&#xD;
             family members. Immediate family is defined as a spouse, parent, child or sibling,&#xD;
             whether biological or legally adopted&#xD;
&#xD;
          -  Are Lilly or Anexon employees or employees of any third-party organization (TPO)&#xD;
             involved with the study that require exclusion of their employees&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email: Anexon@Choruspharma.com</last_name>
    <role>Study Director</role>
    <affiliation>Anexon, Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>July 9, 2012</study_first_submitted>
  <study_first_submitted_qc>July 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2012</study_first_posted>
  <last_update_submitted>October 11, 2017</last_update_submitted>
  <last_update_submitted_qc>October 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Horng Chen</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

